Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues.

International journal of oncology

Arif J, Gairola C, Glauert H, Kelloff G, Lubet R, Gupta R.
PMID: 21528327
Int J Oncol. 1997 Dec;11(6):1227-33. doi: 10.3892/ijo.11.6.1227.

Cigarette smoking plays a major role in the etiology of several human cancers. It is believed that formation of DNA adducts is an initial step in the carcinogenic process. In this study, we have examined the ability of dietary...

Cite
Arif J, Gairola C, Glauert H, et al. Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues. Int J Oncol. 1997;11(6):1227-33doi: 10.3892/ijo.11.6.1227.
Arif, J., Gairola, C., Glauert, H., Kelloff, G., Lubet, R., & Gupta, R. (1997). Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues. International journal of oncology, 11(6), 1227-33. https://doi.org/10.3892/ijo.11.6.1227
Arif, J, et al. "Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues." International journal of oncology vol. 11,6 (1997): 1227-33. doi: https://doi.org/10.3892/ijo.11.6.1227
Arif J, Gairola C, Glauert H, Kelloff G, Lubet R, Gupta R. Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues. Int J Oncol. 1997 Dec;11(6):1227-33. doi: 10.3892/ijo.11.6.1227. PMID: 21528327.
Copy Download .nbib Format: NLM
Observed frustration in confined block copolymers.

Physical review letters

Gallagher PD, Kellogg GJ, Lambooy P, Mayes AM, Russell TP, Satija SK.
PMID: 10056013
Phys Rev Lett. 1994 May 02;72(18):2899-2902. doi: 10.1103/PhysRevLett.72.2899.

No abstract available.

Cite
Gallagher PD, Kellogg GJ, Lambooy P, et al. Observed frustration in confined block copolymers. Phys Rev Lett. 1994;72(18):2899-2902doi: 10.1103/PhysRevLett.72.2899.
Gallagher, P. D., Kellogg, G. J., Lambooy, P., Mayes, A. M., Russell, T. P., & Satija, S. K. (1994). Observed frustration in confined block copolymers. Physical review letters, 72(18), 2899-2902. https://doi.org/10.1103/PhysRevLett.72.2899
Gallagher, et al. "Observed frustration in confined block copolymers." Physical review letters vol. 72,18 (1994): 2899-2902. doi: https://doi.org/10.1103/PhysRevLett.72.2899
Gallagher PD, Kellogg GJ, Lambooy P, Mayes AM, Russell TP, Satija SK. Observed frustration in confined block copolymers. Phys Rev Lett. 1994 May 02;72(18):2899-2902. doi: 10.1103/PhysRevLett.72.2899. PMID: 10056013.
Copy Download .nbib Format: NLM
Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute.

Journal of cellular biochemistry. Supplement

Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG.
PMID: 7616753
J Cell Biochem Suppl. 1994;20:55-62. doi: 10.1002/jcb.240560906.

At the National Cancer Institute, Division of Cancer Prevention and Control, the Chemoprevention Branch and Agent Development Committee develop strategies for efficiently identifying, procuring, and advancing the most promising drugs into clinical trials. Scientific expertise is applied at each...

Cite
Kelloff GJ, Crowell JA, Boone CW, et al. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem Suppl. 1994;20:55-62doi: 10.1002/jcb.240560906.
Kelloff, G. J., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., & Knapp, G. G. (1994). Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. Journal of cellular biochemistry. Supplement, 2055-62. https://doi.org/10.1002/jcb.240560906
Kelloff, G J, et al. "Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute." Journal of cellular biochemistry. Supplement vol. 20 (1994): 55-62. doi: https://doi.org/10.1002/jcb.240560906
Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG. Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem Suppl. 1994;20:55-62. doi: 10.1002/jcb.240560906. PMID: 7616753.
Copy Download .nbib Format: NLM
Chemoprevention strategies in the prostate: an overview.

Reviews in urology

Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED.
PMID: 16985658
Rev Urol. 2002;4(2):69-77.

Chemoprevention is the administration of agents (drugs, biologics, and nutrients) to prevent induction, inhibit, or delay the progression of cancers. Prostate cancer is an important target for chemoprevention because of its long latency and high prevalence. The development of...

Cite
Kelloff GJ, Higley HR, Brawer MK, et al. Chemoprevention strategies in the prostate: an overview. Rev Urol. 2002;4(2):69-77
Kelloff, G. J., Higley, H. R., Brawer, M. K., Lucia, M. S., Sigman, C. C., & Crawford, E. D. (2002). Chemoprevention strategies in the prostate: an overview. Reviews in urology, 4(2), 69-77.
Kelloff, Gary J, et al. "Chemoprevention strategies in the prostate: an overview." Reviews in urology vol. 4,2 (2002): 69-77.
Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED. Chemoprevention strategies in the prostate: an overview. Rev Urol. 2002;4(2):69-77. PMID: 16985658; PMCID: PMC1475973.
Copy Download .nbib Format: NLM
X-ray reflectivity measurements and Landau theory of smectic wetting in liquid crystal-benzyl alcohol mixtures.

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics

Deutsch M, Foster W, Kawamoto EH, Kellogg GJ, Ocko BM, Pershan PS.
PMID: 9963184
Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1995 May;51(5):4709-4726. doi: 10.1103/physreve.51.4709.

No abstract available.

Cite
Deutsch M, Foster W, Kawamoto EH, et al. X-ray reflectivity measurements and Landau theory of smectic wetting in liquid crystal-benzyl alcohol mixtures. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1995;51(5):4709-4726doi: 10.1103/physreve.51.4709.
Deutsch, M., Foster, W., Kawamoto, E. H., Kellogg, G. J., Ocko, B. M., & Pershan, P. S. (1995). X-ray reflectivity measurements and Landau theory of smectic wetting in liquid crystal-benzyl alcohol mixtures. Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics, 51(5), 4709-4726. https://doi.org/10.1103/physreve.51.4709
Deutsch, et al. "X-ray reflectivity measurements and Landau theory of smectic wetting in liquid crystal-benzyl alcohol mixtures." Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics vol. 51,5 (1995): 4709-4726. doi: https://doi.org/10.1103/physreve.51.4709
Deutsch M, Foster W, Kawamoto EH, Kellogg GJ, Ocko BM, Pershan PS. X-ray reflectivity measurements and Landau theory of smectic wetting in liquid crystal-benzyl alcohol mixtures. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1995 May;51(5):4709-4726. doi: 10.1103/physreve.51.4709. PMID: 9963184.
Copy Download .nbib Format: NLM
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.

JCO precision oncology

Williams PM, Forbes T, P Lund S, Cole KD, He HJ, Karlovich C, Paweletz CP, Stetson D, Yee LM, Connors DE, Keating SM, Destenaves B, Cleveland MH, Lau CJ, Barrett JC, Kelloff GJ, McCormack RT.
PMID: 34250423
JCO Precis Oncol. 2021 Jun 01;5. doi: 10.1200/PO.20.00528. eCollection 2021.

We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is considered a cause of...

Cite
Williams PM, Forbes T, P Lund S, et al. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO Precis Oncol. 2021;5doi: 10.1200/PO.20.00528.
Williams, P. M., Forbes, T., P Lund, S., Cole, K. D., He, H. J., Karlovich, C., Paweletz, C. P., Stetson, D., Yee, L. M., Connors, D. E., Keating, S. M., Destenaves, B., Cleveland, M. H., Lau, C. J., Barrett, J. C., Kelloff, G. J., & McCormack, R. T. (2021). Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO precision oncology, 5. https://doi.org/10.1200/PO.20.00528
Williams, P Mickey, et al. "Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health." JCO precision oncology vol. 5 (2021). doi: https://doi.org/10.1200/PO.20.00528
Williams PM, Forbes T, P Lund S, Cole KD, He HJ, Karlovich C, Paweletz CP, Stetson D, Yee LM, Connors DE, Keating SM, Destenaves B, Cleveland MH, Lau CJ, Barrett JC, Kelloff GJ, McCormack RT. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO Precis Oncol. 2021 Jun 01;5. doi: 10.1200/PO.20.00528. eCollection 2021. PMID: 34250423; PMCID: PMC8232894.
Copy Download .nbib Format: NLM
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Clinical cancer research : an official journal of the American Association for Cancer Research

Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer BE, Landgren O, Lightbody ED, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner GA, Valente N, Weiss BM, Zamagni E, Kumar SK.
PMID: 34321279
Clin Cancer Res. 2021 Jul 28; doi: 10.1158/1078-0432.CCR-21-1059. Epub 2021 Jul 28.

The development of novel agents has transformed the treatment paradigm for multiple myeloma (MM), with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and...

Cite
Anderson KC, Auclair D, Adam SJ, et al. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-1059.
Anderson, K. C., Auclair, D., Adam, S. J., Agarwal, A., Anderson, M., Avet-Loiseau, H., Bustoros, M., Chapman, J., Connors, D. E., Dash, A., Di Bacco, A., Du, L., Facon, T., Flores-Montero, J., Gay, F., Ghobrial, I. M., Gormley, N. J., Gupta, I., Higley, H., Hillengass, J., Kanapuru, B., Kazandjian, D., Kelloff, G. J., Kirsch, I. R., Kremer, B. E., Landgren, O., Lightbody, E. D., Lomas, O. C., Lonial, S., Mateos, M. V., Montes de Oca, R., Mukundan, L., Munshi, N. C., O'Donnell, E. K., Orfao, A., Paiva, B., Patel, R., Pugh, T. J., Ramasamy, K., Ray, J., Roshal, M., Ross, J. A., Sigman, C. C., Thoren, K. L., Trudel, S., Ulaner, G. A., Valente, N., Weiss, B. M., Zamagni, E., & Kumar, S. K. (2021). Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-1059
Anderson, Kenneth C, et al. "Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-1059
Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer BE, Landgren O, Lightbody ED, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner GA, Valente N, Weiss BM, Zamagni E, Kumar SK. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 Jul 28; doi: 10.1158/1078-0432.CCR-21-1059. Epub 2021 Jul 28. PMID: 34321279.
Copy Download .nbib Format: NLM
Quantitative imaging for evaluation of response to cancer therapy.

Translational oncology

Clarke LP, Croft BS, Nordstrom R, Zhang H, Kelloff G, Tatum J.
PMID: 19956378
Transl Oncol. 2009 Dec;2(4):195-7. doi: 10.1593/tlo.09217.

No abstract available.

Cite
Clarke LP, Croft BS, Nordstrom R, et al. Quantitative imaging for evaluation of response to cancer therapy. Transl Oncol. 2009;2(4):195-7doi: 10.1593/tlo.09217.
Clarke, L. P., Croft, B. S., Nordstrom, R., Zhang, H., Kelloff, G., & Tatum, J. (2009). Quantitative imaging for evaluation of response to cancer therapy. Translational oncology, 2(4), 195-7. https://doi.org/10.1593/tlo.09217
Clarke, Laurence P, et al. "Quantitative imaging for evaluation of response to cancer therapy." Translational oncology vol. 2,4 (2009): 195-7. doi: https://doi.org/10.1593/tlo.09217
Clarke LP, Croft BS, Nordstrom R, Zhang H, Kelloff G, Tatum J. Quantitative imaging for evaluation of response to cancer therapy. Transl Oncol. 2009 Dec;2(4):195-7. doi: 10.1593/tlo.09217. PMID: 19956378; PMCID: PMC2781068.
Copy Download .nbib Format: NLM
The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals.

Translational oncology

Clarke LP, Nordstrom RJ, Zhang H, Tandon P, Zhang Y, Redmond G, Farahani K, Kelloff G, Henderson L, Shankar L, Deye J, Capala J, Jacobs P.
PMID: 24772201
Transl Oncol. 2014 Feb 01;7(1):1-4. doi: 10.1593/tlo.13832. eCollection 2014 Feb.

The purpose of this editorial is to provide a brief history of National Institutes of Health National Cancer Institute (NCI) workshops as related to quantitative imaging within the oncology setting. The editorial will then focus on the recently supported...

Cite
Clarke LP, Nordstrom RJ, Zhang H, et al. The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. Transl Oncol. 2014;7(1):1-4doi: 10.1593/tlo.13832.
Clarke, L. P., Nordstrom, R. J., Zhang, H., Tandon, P., Zhang, Y., Redmond, G., Farahani, K., Kelloff, G., Henderson, L., Shankar, L., Deye, J., Capala, J., & Jacobs, P. (2014). The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. Translational oncology, 7(1), 1-4. https://doi.org/10.1593/tlo.13832
Clarke, Laurence P, et al. "The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals." Translational oncology vol. 7,1 (2014): 1-4. doi: https://doi.org/10.1593/tlo.13832
Clarke LP, Nordstrom RJ, Zhang H, Tandon P, Zhang Y, Redmond G, Farahani K, Kelloff G, Henderson L, Shankar L, Deye J, Capala J, Jacobs P. The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. Transl Oncol. 2014 Feb 01;7(1):1-4. doi: 10.1593/tlo.13832. eCollection 2014 Feb. PMID: 24772201; PMCID: PMC3998696.
Copy Download .nbib Format: NLM
Guidelines for collecting vouchers and tissues intended for genomic work (Smithsonian Institution): Botany Best Practices.

Biodiversity data journal

Funk VA, Gostel M, Devine A, Kelloff CL, Wurdack K, Tuccinardi C, Radosavljevic A, Peters M, Coddington J.
PMID: 28325986
Biodivers Data J. 2017 Jan 30;(5):e11625. doi: 10.3897/BDJ.5.e11625. eCollection 2017.

No abstract available.

Cite
Funk VA, Gostel M, Devine A, et al. Guidelines for collecting vouchers and tissues intended for genomic work (Smithsonian Institution): Botany Best Practices. Biodivers Data J. 2017;(5):e11625doi: 10.3897/BDJ.5.e11625.
Funk, V. A., Gostel, M., Devine, A., Kelloff, C. L., Wurdack, K., Tuccinardi, C., Radosavljevic, A., Peters, M., & Coddington, J. (2017). Guidelines for collecting vouchers and tissues intended for genomic work (Smithsonian Institution): Botany Best Practices. Biodiversity data journal, (5), e11625. https://doi.org/10.3897/BDJ.5.e11625
Funk, Vicki A, et al. "Guidelines for collecting vouchers and tissues intended for genomic work (Smithsonian Institution): Botany Best Practices." Biodiversity data journal vol. ,5 (2017): e11625. doi: https://doi.org/10.3897/BDJ.5.e11625
Funk VA, Gostel M, Devine A, Kelloff CL, Wurdack K, Tuccinardi C, Radosavljevic A, Peters M, Coddington J. Guidelines for collecting vouchers and tissues intended for genomic work (Smithsonian Institution): Botany Best Practices. Biodivers Data J. 2017 Jan 30;(5):e11625. doi: 10.3897/BDJ.5.e11625. eCollection 2017. PMID: 28325986; PMCID: PMC5345056.
Copy Download .nbib Format: NLM
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Clinical cancer research : an official journal of the American Association for Cancer Research

Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, Hilden P, Ahmed FS, Dercle L, Moskowitz CS, Tang Y, Connors DE, Adam SJ, Kelloff G, Gonen M, Fojo T, Schwartz LH, Oxnard GR.
PMID: 32988968
Clin Cancer Res. 2020 Dec 15;26(24):6464-6474. doi: 10.1158/1078-0432.CCR-20-1493. Epub 2020 Sep 28.

PURPOSE: Mathematical models combined with new imaging technologies could improve clinical oncology studies. To improve detection of therapeutic effect in patients with cancer, we assessed volumetric measurement of target lesions to estimate the rates of exponential tumor growth and...

Cite
Maitland ML, Wilkerson J, Karovic S, et al. Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clin Cancer Res. 2020;26(24):6464-6474doi: 10.1158/1078-0432.CCR-20-1493.
Maitland, M. L., Wilkerson, J., Karovic, S., Zhao, B., Flynn, J., Zhou, M., Hilden, P., Ahmed, F. S., Dercle, L., Moskowitz, C. S., Tang, Y., Connors, D. E., Adam, S. J., Kelloff, G., Gonen, M., Fojo, T., Schwartz, L. H., & Oxnard, G. R. (2020). Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(24), 6464-6474. https://doi.org/10.1158/1078-0432.CCR-20-1493
Maitland, Michael L, et al. "Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,24 (2020): 6464-6474. doi: https://doi.org/10.1158/1078-0432.CCR-20-1493
Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, Hilden P, Ahmed FS, Dercle L, Moskowitz CS, Tang Y, Connors DE, Adam SJ, Kelloff G, Gonen M, Fojo T, Schwartz LH, Oxnard GR. Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clin Cancer Res. 2020 Dec 15;26(24):6464-6474. doi: 10.1158/1078-0432.CCR-20-1493. Epub 2020 Sep 28. PMID: 32988968; PMCID: PMC8170504.
Copy Download .nbib Format: NLM
Strategies for chemoprevention of prostate cancer.

Prostate cancer and prostatic diseases

Kelloff GJ, Lieberman R, Brawer MK, Crawford ED, Labrie F, Miller GJ, Kelloff GJ.
PMID: 12496854
Prostate Cancer Prostatic Dis. 1999 Jan;2:27-33. doi: 10.1038/sj.pcan.4500274.

Because prostate cancer has a long latency and high incidence, it is a good target for chemoprevention by agents such as retinoids, antiandrogens, antiestrogens, and vitamin D analogs. Phase II chemoprevention trials are frequently conducted on cohorts of patients...

Cite
Kelloff GJ, Lieberman R, Brawer MK, et al. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis. 1999;2:27-33doi: 10.1038/sj.pcan.4500274.
Kelloff, G. J., Lieberman, R., Brawer, M. K., Crawford, E. D., Labrie, F., Miller, G. J., & Kelloff, G. J. (1999). Strategies for chemoprevention of prostate cancer. Prostate cancer and prostatic diseases, 227-33. https://doi.org/10.1038/sj.pcan.4500274
Kelloff, G J, et al. "Strategies for chemoprevention of prostate cancer." Prostate cancer and prostatic diseases vol. 2 (1999): 27-33. doi: https://doi.org/10.1038/sj.pcan.4500274
Kelloff GJ, Lieberman R, Brawer MK, Crawford ED, Labrie F, Miller GJ, Kelloff GJ. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis. 1999 Jan;2:27-33. doi: 10.1038/sj.pcan.4500274. PMID: 12496854.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries